Amicus Therapeutics

PA - PhiladelphiaBiotechnology1 H-1B visas (FY2023)

Focus: Amicus Therapeutics is a rare disease-focused biotech company specializing in small-molecule treatments for lysosomal storage disorders and rare cardiovascular conditions. The company derives 98% of revenue from a single peak-stage product (GALAFOLD), positioning it as a highly concentrated, specialist player.

Rare Diseases Cardiovascular

Profile data last refreshed 9h ago · AI intelligence enriched 2w ago

Open Jobs

Recent layoff filing — 58 affected

5/1/2026 — Princeton, NJ · 58 affected · Layoff

Source: state DOL filings via Big Local News

About Amicus Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Amicus Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

GALAFOLD

Fabry Disease

$35M Part D

Peak15.4yr

Anchor product generating 98% of company revenue; small-molecule pharmacological chaperone with 13+ year patent runway and established market position.

Help build intelligence for Amicus Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong pipeline depth in rare diseases with 7 Phase 3 programs across Fabry, Pompe, Gaucher, and epidermolysis bullosa — meaningful drug development trajectory beyond the single revenue driver.
GALAFOLD has patent protection until 2042 and is at peak revenue stage ($35M Part D spending reported), providing 13+ years of commercial stability for the franchise.
Focused therapeutic strategy in lysosomal storage disorders and rare disease creates deep scientific expertise and tight-knit teams familiar with niche regulatory pathways.

Watch Out For

Severe revenue concentration risk: 98% dependency on GALAFOLD creates extreme vulnerability if the drug faces efficacy, safety, or competitive challenges; pipeline programs remain pre-commercial.
Recent layoff event (May 2026, 58 employees in Princeton, NJ) signals financial or strategic pressure; zero active job openings at time of data snapshot suggests near-term hiring freeze.
Small employee base and limited hiring footprint indicate constrained career growth and advancement opportunities compared to larger biotech platforms.

Pipeline & Clinical Trials

Survey

Epidermolysis Bullosa

N/A

Clinical Trials (1)

NCT03158662Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

N/A

dry blood test

Fabry Disease

N/A

Clinical Trials (1)

NCT04184986Screening of Fabry Disease in Patients With GI Symptoms

N/A

Noninterventional characterization of patients expectations and preferences regarding their treatment

Fabry Disease

N/A

Clinical Trials (1)

NCT04043273Treatment-related Benefit and Satisfaction in Fabry Patients. Insight in Patients Expectations and Preferences

N/A

Observation

Pompe Disease

N/A

Clinical Trials (4)

NCT04252066A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

N/A

NCT04602364French Prospective, Observational Cohort Study of Patients With Fabry Disease Treated With Migalastat

Blood sample

Gaucher Disease

N/A

Clinical Trials (1)

NCT00351156Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

N/A

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Late-onset Pompe Disease

N/A

Clinical Trials (1)

NCT03347253STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

N/A

This is a non-interventional study

Fabry Disease

N/A

Clinical Trials (1)

NCT04804566Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

N/A

Enzyme Replacement Therapy

Fabry Disease

N/A

Clinical Trials (2)

NCT01218659Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Phase 3

NCT04281537A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.

Diet and Exercise

Pompe Disease

N/A

Clinical Trials (1)

NCT02363153Diet and Exercise in Pompe Disease

N/A

Real World Evidence Study of Danish Fabry Patients

Fabry Disease

N/A

Clinical Trials (1)

NCT06303466Real World Evidence Study of Danish Fabry Patients

N/A

BNP blood sample test

Hypertrophic Cardiomyopathy

N/A

Clinical Trials (1)

NCT04129905Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies

N/A

Zavesca® Prescription

Pompe Disease

Phase 1

Clinical Trials (1)

NCT02185651A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction

Phase 1

AT2101

Type 1 Gaucher Disease

Phase 1

Clinical Trials (4)

NCT00433147A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy

Phase 2

NCT00446550A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease

GR181413A/AT1001 solution

Fabry Disease

Phase 1

Clinical Trials (1)

NCT01853852A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

Phase 1

afegostat

Gaucher Disease, Type 1

Phase 2

duvoglustat

Pompe Disease

Phase 2

Clinical Trials (2)

NCT00688597Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

Phase 2

NCT01380743Drug-drug Interaction Study

Phase 2

amisulpride

Nausea and Vomiting, Postoperative

Phase 2/3

miglustat

Pompe Disease

Phase 3

cipaglucosidase alfa

Pompe Disease

Phase 3

Clinical Trials (4)

NCT04808505A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Phase 3

NCT03729362A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

AT2221

Pompe Disease

Phase 3

Clinical Trials (4)

NCT04138277A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)

Phase 3

NCT02675465First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

migalastat

Fabry Disease

Phase 3

Clinical Trials (5)

NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

Phase 3

NCT01458119Open-Label Phase 3 Long-Term Safety Study of Migalastat

Phase 3

SD-101

Epidermolysis Bullosa

Phase 3

Clinical Trials (4)

NCT02384460ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Phase 3

NCT02670330Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Interview Prep Quick Facts

Portfolio: 4 approved products, 55 clinical trials

Top TAs: Rare Diseases, Cardiovascular

H-1B (2023): 1 approval

Publications: 26 in PubMed

Portfolio Health

Growth2 (50%)

Peak1 (25%)

Post-LOE1 (25%)

4 total products

Therapeutic Area Focus

Rare Diseases

4 marketed48 pipeline

Cardiovascular

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (1)

2026-05-01

58 employees affected— Princeton, NJ

Source: state DOL filings, aggregated via Big Local News

May 2026 layoff of 58 employees (Princeton facility) signals cash or strategic restructuring; aligns with zero active job openings.

Recent and material layoff activity; company is under financial or operational pressure despite GALAFOLD revenue — high execution risk over next 12–24 months.

Private Funding (SEC Form D)

Dec 2013

Jul 2012

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Therapeutic advances in rare disease

2026

PMID:41769220

Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials.

Amicus Therapeutics

About Amicus Therapeutics

Why Work Here

Key Products

Watch Out For

Products & Portfolio (3)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Recent News · Amicus Therapeutics(10)

Open Jobs (0)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (1)

Private Funding (SEC Form D)

Research Publications(10)